A Royal Marsden Cancer Charity annual fundraiser that involves 30,000 illuminated white roses on display in a remembrance garden in central London has raised more than £1m since its launch five years ago.

The Ever After Garden takes place during November and December and sees the lit-up flowers in place in Grosvenor Square, London.

Following 2024’s fundraiser the charity has announced that £1.2m has been raised since it began.

Corporate support is from the firm Grosvenor, which is involved in property and estate management and is a founding partner of the garden.

The fundraiser’s corporate headline partner is Brookfield Asset Management.

In the garden supporters of the charity can pay a minimum of £10 to dedicate one of the roses to a loved one. Visitors can also donate to the charity.

The garden was founded by the charity’s trustee Anya Hindmarch and inspired be her friend and cinema production designer the late Michael Howells, whose work included the film Ever After. Fashion writer Camilla Morton is another co-founder.

“We are so grateful to everyone who has dedicated a rose in the Ever After Garden,” said Hindmarch.

“Each dedication has contributed to this incredible fundraising milestone for The Royal Marsden Cancer Charity, which does such important work to help improve the lives of cancer patients at The Royal Marsden, as well as across the UK and the world.

“I am hugely proud that the Ever After Garden continues to have a tremendous impact through the funds it raises, and by offering comfort, hope and a feeling of community to those who are missing their loved ones.”

The charity’s managing director Antonia Dalmahoy added: “Reaching this fundraising milestone is a testament to the hard work of Anya Hindmarch and Camilla Morton, who have been the driving force behind the Ever After Garden and its remarkable success since it began.

“The generosity of everyone who has dedicated a rose in the Ever After Garden makes a vital difference by helping the Charity to fund life-saving research, from innovative clinical trials to the development of new drugs, which benefit cancer patients and their loved ones across the world.”

---